Pharma Turkey Dergisi Eylül – Ekim 2017 Sayısı

More documents

Recommendations

Info

“Nuclear medicine will play a very serious role in diagnosis and treatment of Parkinson and Alzheimer” Leading the health sector in the field of nuclear medicine, Eczacıbaşı – Monrol continues to expand the areas of nuclear medicine with R & D activities in Turkey. Entering the field of nuclear medicine with Bozlu Grup in 2008, Eczacıbaşı has increased its investment by noticing growth potential of Monrol which it received 50% firstly then increased to 84%. Arising from a combination of experience and technical knowledge of Monrol’s founders and Eczacıbaşı’s power, synergies and experience in the field of health, Eczacıbaşı - Monrol will continue its pioneering activities with this power. Declaring that he has been in the health sector for 20 years, Mustafa Aydin Kucuk, General Manager of Eczacıbaşı - Monrol informed about their activities in nuclear medicine and objectives. Can you inform us about Eczacıbaşı Monrol briefly? We are a production company. We also import and export some of our products. We are a company in the field of radiopharmaceuticals having the widest range of products. Monrol produced the first FDG PET products in Turkey, after TAEG had produced spect products, Monrol made first manufacturing in the private sector. Radioactive pharmaceutical production is a niche area. The drugs are used in both diagnosis and treatment. The financial size of the industry is relatively small compared to other fields in the pharmaceutical sector, so the number of people specialized in this field are less. We are the company with most many plants in Turkey. Other companies are doing just the general production in Istanbul. We have now facilities in 28 Pharma September- October ‘17 Istanbul, Ankara, Antalya, Izmir and Adana. We can deliver our products to all over Turkey. It matters; because it is supposed to be given to patients within 6.5 hours when the products are manufactured, or product is running out and the radioactivity ends. So this is a very difficult operation ... and production being done at night. From there it is taken again by specially trained teams with special vehicles and taken to the hospital. It is not a stockable product. Most of the short half-life FDG diagnostic agent that is usually used as a diagnostic product by applying a special diet within a day or two with the patient’s knowledge. For example, PET scanning of one patient from Van will be held on Thursday, its preparations are made on Tuesday or Wednesday and products are getting ready. Obstacles such as weather conditions come up, but we have the ability to deliver that product to the region. Drugs are already losing its influence if can not be delivered on time. Although we have a huge advantage in terms of geographic distribution, the operation is costly. The cost of providing a plant is also very high.Our product is one method with gold standards for the diagnosis and staging of cancer. This is used for imaging the brain mainly cancer, cardiac imaging, thyroid imaging, imaging of renal function. None of the other imaging techniques are effective. Our treatment products also exist, some of these products called as atom treatment colloquially. Mentioning products are essentially iodine for the treatment of thyroid cancer. What is your annual production rate? We have 150,000 patients a year. There are about 130,000 new cancer patients every year in Turkey. We are dealing with more than 150,000 patients both at home and abroad. Our market share varies between 50% and 60%. The remaining needs are met by the other companies in the sector. They also have similar production and logistics networks, but they all just have production in Istanbul. How do we relate to the public? Do the public demand from you? Or are you only active in the private sector? The public has 90% share of health system in Turkey and we are also working with the public as well. Directly we have the public contract, and also we offer our products indirectly to the public. Are your competitors mostly domestic companies? There are three domestic producers of FDG. There is an international company that cooperates with Turkish producers in SPECT field. They’ve got a good market share but we protect 60% of our share in SPECT. We also have a Theranostics field for both diagnosis and treatment. We continue to grow in that area as well.
What are the goals you set for the Turkish market? We have a common distribution channel and it is very important for these patients. We’re in production of existing licensed products, but also a leading government agency. FDG agent, is now known and widely used. We are also R & D and P & D. In Turkey, there is no other organization with that extensive R & D and P & D team. Both in Gebze we have our own R & D and P & D team. In addition, we cooperate with Ankara University. We are developing common drugs at the RÜAG facility with Ankara University. These drugs are in the literature, but we are developing these drugs for the first time in Turkey. Some are used in the diagnosis of cancers and some other for diseases. In Alzheimer’s disease, including brain scanning can also be used. Our R & D team are trying to develop with our instructor at Ankara University and even doing animal experiments. Even less so in Europe, which began to give the first fruits of the work we do at this facility. We were able to produce a very special product such as Fluorodopan to (FDOPA) and Floroestradiol (FES) there. We have not yet realized the stage of licensing, but will be presented to the service of our people once they are licensed. Parkinson’s and Alzheimer’s disease in the FDOPA being used, you know that Alzheimer’s is still an incurable disease. States spend less due to there is no treatment for this disease. Now Alzheimer’s diagnosis not available but FDG PET and F DOPA scanning is an important touchstone for diagnostic of AD and PD. Probably nuclear medicine will play a very serious role in diagnosis and treatment of Alzheimer and Parkinson. We expect it to be in the immunotherapy and genetically and these are new cancer diagnosis and treatment systems. Nuclear medicine will play a very important role in this field and we started our work. You are doing big investments in Turkey. Do you get along with state authority and give incentives? We use certain incentives when we made investments but we want to use more incentives in research and development activities. There are a number of incentives that we can use. Maybe more can be done. We can even produce these products abroad, we can export. But our dimension is a bit small. So we are below the thresholds of these incentives. Do you want to meet your overseas demands by exporting or by making production in that region? We also have overseas facilities in production. We have our own facilities in Romania, Bulgaria and Egypt. Apart from that, we are producing contracted products in Kuwait and Dubai. We are probably there for 10 years as we carry out our production and we are regularly inspected by authorities in both of these countries as well as Turkey TAEK are regularly inspected by the Ministry of Health. Making radioactive drug production has a huge responsibility. The knowledge and experience here is very important. Beneficial to public health fits under control and we are able to fulfill these even in very difficult geography. Do the states in the region you are investing support you? They do not provide. Even not entering the European Union. We realized even install facilities in Bulgaria, Romania and Poland. The conditions were very difficult and there was no other production facility. Cancer patients there find healing with our products patients with diagnosis of Nuclear Medicine started to improve the health standards of those countries. In this way, the healthcare service is also getting cheaper because it is not a cheap diagnosis in total, but when you look at the total cost of treatment for a cancer patient, it seriously reduces the overall cost. You apply the right treatment available in early diagnosis. Nuclear medicine is the best way of learning that drug is effective or not. We provide a serious development of oncology and cardiology as well as nuclear medicine. I can say that we can clearly see the development of the health system in the places we go. In these regions, demand was difficult to achieve in the first year, but demand occurs much later. Firstly, doctors and health professionals must be trained. “Radioactivity damage people and environment fear” can exist. The result is a diagnosis widely used in the United States and developed countries. If it’s planned, it doesn’t harm the person. Are there any other countries where you want to invest? We are interested in developing geographies if there is local investors. In our production, we are exporting to 25 countries in longterm isotopes up to India. We rely on the network of Turkish Airlines in our transfers within the country. The airline is important because our products needs to be on plane and shipped very quickly. In the place we refer to, a special team meets our product and takes them to the hospital immediately. What do you want to add? We attach great importance for new products. There are some products that can be brought from abroad but only we can produce them. In this sense, we also need more support from the government. You are investing in facilities, but you are having difficulty maintaining continuity when there is a problem with that test. If we enter in procurement contracts and says that you’re doing, but three times, it was announced and banned if you can not deliver. You can not make a backup of the facility because it is not economically sufficient. If you do not establish any facilities, Turkey will not benefit from it unless you enter the tender. Patients will either be victims or will come from abroad at high cost, loss of foreign exchange. But if there are disruptions in the production of our products making up impasses like the state of being banned from bidding. Such a special exception should be in the public should be supported, I think. Awareness of nuclear medicine in developing regions for particular item is too low, but this is also a critical area. More important element that this is a field, which will have more space than today in the diagnosis and treatment in the long term. We are searching every area for diagnosis and treatment as well as nuclear medicine. Pharma September- October ‘17 29
Page 1: September-October 2017 A
Page 4 and 5: 2 Pharma September- October ‘17
Page 6 and 7: Publisher Ferruh IŞIK on behalf of
Page 8 and 9: Akıllı ilaçlarla umutlar artıyo
Page 10 and 11: Hopes raising with smart drugs An i
Page 12 and 13: Kanser tedavisinde yeni bir seçene
Page 14 and 15: Hematolojik kanserlerin tedavisinin
Page 16 and 17: We can now transfer to any patient
Page 18 and 19: DEVA, EU GMP sertifikalı tesisleri
Page 20: DEVA receives FDA approval with EU
Page 23 and 24: Trimbow ® (ICS/LABA/LAMA) Avrupa
Page 25 and 26: The FDA-approved drug VENCLYXTO (v
Page 28 and 29: “Nükleer tıp Parkinson ve Alzhe
Page 32 and 33: Kilo vermenin dayanılmaz hafifliğ
Page 34: The unbearable lightness of weight
Page 37 and 38: Two major transfers abroad in The N
Page 40 and 41: Berko İlaç sürdürülebilirliği
Page 42 and 43: Romatoid artrit tedavisinde kullan
Page 44: Kaliteli ve Sürdürülebilir Bir S
Page 48 and 49: Türk ilacının kalitesi dünyada
Page 50: The quality of Turkish medicine is
Page 53 and 54: Uluslararası Katılımlı Ulusal S
Page 55 and 56: 2. İstanbul Ulusal Beslenme ve Diy
Page 58 and 59: Hazırlayanlar: Ebru PEKEL - Recep
Page 60 and 61: Bayraktar Grubu’nda organizasyone
Page 62 and 63: Kordsa ve Continental Güçlerini B
Page 64: İkinci El Araçta Konforun Yeni Ad

Pharma Turkey Dergisi Eylül – Ekim 2017 Sayısı

Create successful ePaper yourself

Delete template?

Save as template?